ECSP21018584A - Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 - Google Patents

Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6

Info

Publication number
ECSP21018584A
ECSP21018584A ECSENADI202118584A ECDI202118584A ECSP21018584A EC SP21018584 A ECSP21018584 A EC SP21018584A EC SENADI202118584 A ECSENADI202118584 A EC SENADI202118584A EC DI202118584 A ECDI202118584 A EC DI202118584A EC SP21018584 A ECSP21018584 A EC SP21018584A
Authority
EC
Ecuador
Prior art keywords
ccr6
hydroxy
substituted
dioxocyclobutenylamine
picolinamides
Prior art date
Application number
ECSENADI202118584A
Other languages
English (en)
Inventor
Robinson, Jr
Daniel Copley Schmitt
Mark Edward Schnute
Atli Thorarensen
Huixian Wu
Andrew Christopher Flick
Philippe Marcel Nuhant
Daniel Wei-Shung Kung
Rayomand Jal Unwalla
Vincent Michael Lombardo
Brian Stephen Gerstenberger
John Isidro Trujillo
James John Mousseau
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP21018584A publication Critical patent/ECSP21018584A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de dioxociclobutenilamino-3-hidroxi-picolinamida N-sustituida de las Fórmulas (IA y IB), conforme se desprende del resumen de la memoria técnica, o una sal o hidrato de aquellos aceptables desde el punto de vista farmacéutico, que inhiben el receptor de quimiocinas CC 6 (CCR6), a composiciones farmacéuticas que contienen estos compuestos, y al uso de estos compuestos para tratar o prevenir enfermedades, afecciones o trastornos que mejoran mediante inhibición de CCR6.
ECSENADI202118584A 2018-09-21 2021-03-16 Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 ECSP21018584A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862734486P 2018-09-21 2018-09-21

Publications (1)

Publication Number Publication Date
ECSP21018584A true ECSP21018584A (es) 2021-04-29

Family

ID=68051869

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202118584A ECSP21018584A (es) 2018-09-21 2021-03-16 Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6

Country Status (32)

Country Link
US (3) US10975065B2 (es)
EP (1) EP3852879A1 (es)
JP (1) JP6989729B2 (es)
KR (2) KR102615234B1 (es)
CN (2) CN116874466A (es)
AR (1) AR116464A1 (es)
AU (1) AU2019344107B2 (es)
BR (1) BR112021003956A2 (es)
CA (1) CA3055805A1 (es)
CL (1) CL2021000683A1 (es)
CO (1) CO2021003391A2 (es)
CR (1) CR20210146A (es)
CU (1) CU20210016A7 (es)
DO (1) DOP2021000045A (es)
EA (1) EA202190586A1 (es)
EC (1) ECSP21018584A (es)
GE (2) GEP20237476B (es)
IL (1) IL281634B2 (es)
MA (1) MA53643A (es)
MX (1) MX2021003318A (es)
MY (1) MY209296A (es)
NI (1) NI202100012A (es)
NZ (1) NZ773473A (es)
PE (1) PE20211070A1 (es)
PH (1) PH12021550554A1 (es)
PY (1) PY1978496A (es)
SG (1) SG11202101827RA (es)
TW (1) TWI754172B (es)
UA (1) UA128700C2 (es)
UY (1) UY38379A (es)
WO (1) WO2020058869A1 (es)
ZA (1) ZA202101169B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211070A1 (es) * 2018-09-21 2021-06-09 Pfizer Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6
UA130467C2 (uk) * 2020-04-30 2026-02-25 Ідорсія Фармасьютікалз Лтд Похідні азетидин-3-ілметанолу як модулятори рецептора ccr6
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
KR20240090695A (ko) 2021-10-26 2024-06-21 이도르시아 파마슈티컬스 리미티드 Ccr6 수용체 조절인자
IL312369A (en) * 2021-10-28 2024-06-01 Idorsia Pharmaceuticals Ltd CCR6 receptor modulators
CN116162081B (zh) * 2022-12-13 2024-08-09 药康众拓(江苏)医药科技有限公司 一类氘代吡啶酰胺类ccr6抑制剂药物及用途
WO2024222865A1 (zh) * 2023-04-28 2024-10-31 武汉朗来科技发展有限公司 作为ccr6拮抗剂的化合物、其药物组合物和用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354763A (en) 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5466712A (en) 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
ES2128774T3 (es) 1994-11-16 1999-05-16 American Home Prod Diaminociclobuten-3,4-dionas.
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
US6495576B2 (en) 2001-02-07 2002-12-17 Abbott Laboratories Aminal diones as potassium channel openers
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
ES2287284T3 (es) 2001-04-16 2007-12-16 Schering Corporation Ciclobuteno-1,2-dionas disustituidas en las posiciones 3,4 como ligandos de receptores de quimiocinas cxc.
US20040053953A1 (en) 2002-03-18 2004-03-18 Schering Corporation Treatment of chemokine mediated diseases
CN1720240B (zh) * 2002-10-09 2010-10-27 先灵公司 作为cxc-和cc-趋化因子受体配体的噻二唑二氧化物和噻二唑氧化物
ATE523506T1 (de) 2005-02-16 2011-09-15 Schering Corp Amingebundene pyridyl- und phenylsubstituierte piperazin-piperidine mit cxcr3-antagonistischer aktivität
AU2007233173A1 (en) 2006-03-31 2007-10-11 Janssen Pharmaceutica N.V. 3,4-diamino-3-cyclobutene-1,2-dione derivatives as potassium channel openers
MX2008015004A (es) 2006-05-26 2008-12-05 Abbott Lab Inhibidores de cinasas de tipo polo.
US20080045489A1 (en) 2006-07-07 2008-02-21 Jianhua Chao 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
CA2685529A1 (en) 2007-04-30 2008-11-06 Abbott Laboratories Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
ATE554066T1 (de) 2007-06-06 2012-05-15 Novartis Ag Entzündungshemmende substituierte cyclobutendionverbindungen
CN101778836A (zh) 2007-07-05 2010-07-14 先灵公司 在1,2-取代的3,4-二氧-1-环丁烯化合物中控制的晶体大小的方法
WO2009012375A2 (en) 2007-07-19 2009-01-22 Wyeth Squarate kinase inhibitors
CN101808990B (zh) 2007-07-24 2012-09-05 百时美施贵宝公司 作为趋化因子受体活性调节剂的哌啶衍生物
JP2010534669A (ja) 2007-07-24 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー ケモカイン受容体活性のモジュレーターとしての非環式誘導体
CA2706883A1 (en) 2007-12-04 2009-06-11 Schering Corporation Methods of treating copd
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010131145A1 (en) * 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
CA2771822C (en) 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
MX2012005463A (es) 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
FR2961695B1 (fr) 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US8648118B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted amide functionalised phenols as medicaments
US8648070B2 (en) 2010-12-17 2014-02-11 Boehringer Ingelheim International Gmbh Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments
JP2014525443A (ja) 2011-08-30 2014-09-29 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物、およびこれらの使用方法
FR2981935B1 (fr) 2011-10-28 2015-08-07 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981934B1 (fr) * 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
FR2981936B1 (fr) 2011-10-28 2013-12-20 Galderma Res & Dev Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
AU2013265266A1 (en) 2012-05-23 2015-01-15 Stemergie Biotechnology Sa Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof
ES2715682T3 (es) 2012-12-19 2019-06-05 Novartis Ag Inhibidores de la autotaxina
CN104936949A (zh) 2013-01-25 2015-09-23 百时美施贵宝公司 用于治疗丙型肝炎的squaric衍生物
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
FR3030515B1 (fr) 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
US10660909B2 (en) * 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
PE20211070A1 (es) * 2018-09-21 2021-06-09 Pfizer Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas utiles como inhibidores de ccr6

Also Published As

Publication number Publication date
PE20211070A1 (es) 2021-06-09
IL281634A (en) 2021-05-31
CU20210016A7 (es) 2021-10-12
CN112672791A (zh) 2021-04-16
CN116874466A (zh) 2023-10-13
AR116464A1 (es) 2021-05-12
PH12021550554A1 (en) 2022-02-21
KR20210046717A (ko) 2021-04-28
IL281634B1 (en) 2024-10-01
CN112672791B (zh) 2023-10-03
TW202024056A (zh) 2020-07-01
CR20210146A (es) 2021-05-20
US20210206757A1 (en) 2021-07-08
KR102615234B1 (ko) 2023-12-19
CA3055805A1 (en) 2020-03-21
GEAP202215588A (en) 2022-11-10
MX2021003318A (es) 2021-05-14
US12312344B2 (en) 2025-05-27
US11708360B2 (en) 2023-07-25
US10975065B2 (en) 2021-04-13
JP2021532166A (ja) 2021-11-25
MA53643A (fr) 2021-12-29
GEP20237476B (en) 2023-03-27
CL2021000683A1 (es) 2021-10-15
UY38379A (es) 2020-04-30
WO2020058869A1 (en) 2020-03-26
KR102755257B1 (ko) 2025-01-14
US20240368144A1 (en) 2024-11-07
TWI754172B (zh) 2022-02-01
JP6989729B2 (ja) 2022-01-05
CO2021003391A2 (es) 2021-04-08
EA202190586A1 (ru) 2021-07-05
AU2019344107B2 (en) 2022-09-15
EP3852879A1 (en) 2021-07-28
ZA202101169B (en) 2022-07-27
MY209296A (en) 2025-07-01
NI202100012A (es) 2021-06-22
KR20230175326A (ko) 2023-12-29
NZ773473A (en) 2023-07-28
UA128700C2 (uk) 2024-10-02
SG11202101827RA (en) 2021-04-29
PY1978496A (es) 2020-04-20
BR112021003956A2 (pt) 2021-05-25
US20200095239A1 (en) 2020-03-26
IL281634B2 (en) 2025-02-01
DOP2021000045A (es) 2021-04-30
AU2019344107A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
ECSP21018584A (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CU20170154A7 (es) Derivados de pirazol-3-il-amina sustituidos como inhibidores cdk
CU20180006A7 (es) Compuestos de indazaol y azaindazol como inhibidores de irak-4
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
CL2020001020A1 (es) Derivados de bencimidazol y sus usos.
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
ECSP20066271A (es) Derivados de pirazo-tetrahidroisoquinolina como moduladores positivos del receptor de dopamina d1
CL2025001536A1 (es) Derivados de morfolinas sustituidas y usos de estos
CU20200102A7 (es) Compuestos derivados de isoindolin-1,2,4-triazol-3-carbonitrilo útiles para el tratamiento de enfermedades cinetoplastídicas
PH12021550258A1 (en) Cdk8/19 inhibitors
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
UY38133A (es) Nuevos inhibidores de cdk8/19
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
EA202190339A1 (ru) Пиридопиримидины в качестве ингибиторов н4-гистаминовых рецепторов
ECSP20003493A (es) Composiciones farmacéuticas
EA202090241A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19
AR111416A2 (es) Compuesto terapéutico para el dolor y síntesis del compuesto
EA202190043A2 (ru) Замещенные гетероциклические производные как ингибиторы циклин-зависимой киназы (cdk)
BR112018015851A2 (pt) composto, e, medicamento.
CU20160170A7 (es) Derivados de carboxamida
GB2553685A8 (en) Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis